Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127


Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators.

N Engl J Med. 2004 Nov 11;351(20):2058-68. Epub 2004 Nov 7.


A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.

Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC.

N Engl J Med. 1995 Dec 21;333(25):1670-6.


[Peace-study. Coronary heart disease: additive therapy with ACE-inhibitors?].

Böhm M.

Internist (Berl). 2005 May;46(5):592-4. German. No abstract available.


ACE inhibition in secondary prevention: are the results controversial?

Friedrich EB, Teo KK, Böhm M.

Clin Res Cardiol. 2006 Feb;95(2):61-7. Epub 2006 Jan 16.


Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.

Lancet. 2003 Sep 6;362(9386):782-8.


Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.

N Engl J Med. 2000 Jan 20;342(3):145-53. Erratum in: 2000 May 4;342(18):1376. N Engl J Med 2000 Mar 9;342(10):748.


Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study.

Torp-Pedersen C, Køber L, Carlsen J.

Am Heart J. 1996 Jul;132(1 Pt 2 Su):235-43.


Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.

Rouleau JL, Warnica WJ, Baillot R, Block PJ, Chocron S, Johnstone D, Myers MG, Calciu CD, Dalle-Ave S, Martineau P, Mormont C, van Gilst WH; IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators.

Circulation. 2008 Jan 1;117(1):24-31. Epub 2007 Dec 10.


The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).

Kjøller-Hansen L, Steffensen R, Grande P.

J Am Coll Cardiol. 2000 Mar 15;35(4):881-8.


Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.

Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O'Donnell TF, Vora AN, Omland T, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MS.

J Am Coll Cardiol. 2014 Jun 10;63(22):2421-8. doi: 10.1016/j.jacc.2014.03.026. Epub 2014 Apr 9.


Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.

Solomon SD, Rice MM, A Jablonski K, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E; Prevention of Events with ACE inhibition (PEACE) Investigators.

Circulation. 2006 Jul 4;114(1):26-31. Epub 2006 Jun 26.


Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy.

Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, Solomon SD, Domanski MJ, Jablonski KA, Rice MM, Pfeffer MA; Prevention of Events With Angiotensin-Converting Enzyme Inhibition Investigators.

Hypertension. 2007 Jun;49(6):1271-7. Epub 2007 Apr 23.


Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.

Peters DC, Noble S, Plosker GL.

Drugs. 1998 Nov;56(5):871-93. Review.


Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition.

Pfeffer MA, Domanski M, Rosenberg Y, Verter J, Geller N, Albert P, Hsia J, Braunwald E.

Am J Cardiol. 1998 Aug 6;82(3A):25H-30H.


Supplemental Content

Support Center